Canada Royal Enoch Phytomedicine Ltd., an innovative leader in ginseng and ginsenosides research and application, is proud to announce that Health Canada approved its clinical trial application testing the safety and efficacy of Redsenol Noble Ginsenosides for treating cancer-related fatigue.
"The approval of the clinical trial application is a significant milestone in our ginsenoside research," stated Dr. Peihua Yu, CEO & President of Canada Royal Enoch Phytomedicine. "We tested the anti-proliferation effects of Redsenol Noble Ginsenosides in different tumor cell lines in 2015, and this time we moved a big step forward to conduct a in-human trial."
The clinical trial will be a randomized, triple-blind, placebo controlled, parallel study involving 72 participants, and is expected to begin in early 2023.
Canada Royal Enoch Phytomedicine is engaged in the research, production and sales of natural plant-based products. The company remains its technology competitiveness in industrialized production of rare ginsenosides, and its four unique technologies in rare ginsenoside extraction, processing, transformation, and formulation enable the preparation of easily absorbable rare ginsenosides.
Redsenol, developed by Canada Royal Enoch Phytomedicine, is a top ginseng supplement brand featuring multicomponent rare ginsenosides in high concentration. Redsenol Series offers highly bioactive and absorbable rare ginsenoside monomers Rg3, Rh2, Rk1, Rg5, Rh3, Rk2, aPPD(S, R), aPPT(S, R), more potent than common Panax/Korean red ginseng extracts.